Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multiple Center, Open-label Phase III Study to Evaluate Long-term Safety of BR005-036C Tablets for the Acute Treatment of Migraine in Adults

NCT07835152 is registered in ClinicalTrials.gov with Brise Pharmaceuticals Co., Ltd. as lead sponsor.

NCT NCT07835152
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07835152 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multiple Center, Open-label Phase III Study to Evaluate Long-term Safety of BR005-036C Tablets for the Acute Treatment of Migraine in Adults
Lead sponsor
Brise Pharmaceuticals Co., Ltd.
Phase
Phase 3
Overall status
Not yet recruiting
Start date
September 30, 2026
Completion date
April 30, 2029
Enrollment
1,000 (estimated)
Sites
81

Conditions

As the registry lists them; a condition with its own page is linked.

migraine, with or without aura